Antibody Responses in Contacts of COVID-19 Patients
Antibody Responses in Asymptomatic Close Contacts of COVID-19 Patients and Their Implications
1 other identifier
observational
100
1 country
1
Brief Summary
After several cases of pneumonia with an unfamiliar etiology were observed at the end of 2019, the National Health Commission of China released more details about the epidemic in early 2020. The pathogen was identified as a novel coronavirus and named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as it has a phylogenetic similarity to SARS-CoV. Since then, SARS-CoV-2 has spread rapidly and the resulting coronavirus disease 2019 (COVID-19) has been declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO). SARS-CoV-2 is highly contagious, and there has not yet been any vaccine or effective treatment that has received approval. So, the best solution for controlling the pandemic will be the simultaneous application of preventive methods, sensitive diagnostic approaches, and using current available drugs, while still developing novel treatments. Coronaviruses are enveloped, non-segmented, single positive-stranded RNA viruses with round or oval particles and a diameter of 50-200 nm. Coronavirus subfamily is divided into four genera: α, β, γ and δ according to serotype and genomic characteristics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 18, 2020
CompletedFirst Submitted
Initial submission to the registry
June 19, 2020
CompletedFirst Posted
Study publicly available on registry
June 23, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2020
CompletedJune 23, 2020
June 1, 2020
3 days
June 19, 2020
June 21, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Measure level of Abs in asymptomatic close contacts of COVID 19 patients.
serum level of antiSARS-CoV-2 IgG, IgM
one day
Eligibility Criteria
asymptomatic close contacts of confirmed COVID-19 patients, not complaining
You may qualify if:
- close contacts of confirmed COVID-19 patients, apparently healthy
You may not qualify if:
- symptomatic close contacts, any close contacts with malignant tumor, stroke, cardiac, respiratory, Gastrointestinal, and renal diseases or any organ dysfunction.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AssiutU
Asyut, 71111, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 14 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Pulmonology
Study Record Dates
First Submitted
June 19, 2020
First Posted
June 23, 2020
Study Start
June 15, 2020
Primary Completion
June 18, 2020
Study Completion
September 30, 2020
Last Updated
June 23, 2020
Record last verified: 2020-06